Silence Therapeutics names David Horn Solomon as CEO
Silence Therapeutics has announced the appointment of Dr David Horn Solomon, an experienced public company biotech boss and biotech investor as its new chief executive officer (CEO). Dr Solomon was previously the CEO of Zealand Pharma A/S, from 2008 to 2015, and has also been the CEO of Bionor Pharma ASA and Akari Therapeutics.
Under his leadership, Zealand Pharma went public on NASDAQ OMX and its lead product, Adlixin, a GLP1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by French drugs firm Sanofi as a monotherapy and in combination with Lantus as Soliqua.
He has an extensive experience in pharmacology research. He has more than 20 years of experience in medical research, healthcare investing and key biopharmaceutical & medical device operating roles. He served leadership positions at several biotechnology, pharmaceutical and medical device companies, including Critical Diagnostics.